Nivolumab, as an all human IgG4 monoclonal antibody, evaluated a cohort of 493 advanced GC Asian patients (regardless of programmed cell death ligand 1 status) who received at least two systematic regimens in a phase III clinical study. This evidence concerns the gene CD274 and gastric cancer.